A 26-year-old woman with a history of mild mental retardation, Charcot-Marie-Tooth disease (CMT) and idiopathic thrombocytopenic purpura developed severe thrombocytopenia with Coombs-negative hemolytic anemia. Magnetic resonance imaging revealed a fresh cerebral infarction in the left precentral gyrus. ADAMTS-13 deficiency caused by an inhibitor and anti-cardiolipin antibodies were detected in the blood. After treatment with prednisolone and fresh frozen plasma, ADAMTS-13 activity was normalized, the ADAMTS-13 inhibitor had disappeared and the thrombocytopenia with a bleeding tendency was improved. To our knowledge, this is the first case of thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency associated with antiphospholipid antibodies and CMT.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is characterized by hemolytic anemia with schistocytes on blood smears, thrombocytopenia, fever, systemic occlusion of the microcirculation that frequently leads to renal abnormalities, and neurologic disturbances (1) . ADAMTS-13 (a disintegrinlike metalloprotease with thrombospondin type 1 domain 13) deficiency is the major cause of TTP (2) . Under normal conditions, unusually large von Willebrand factor multimers (UL-VWFM) are rapidly cleaved and degraded into smaller VWFM by ADAMTS-13. However, because most patients diagnosed with idiopathic TTP show a severe deficiency of functional ADAMTS-13 (3) (4) (5) , UL-VWFM circulating in the plasma of TTP patients actively interacts with platelets, inducing the formation of platelet thrombi under conditions of high shear stress (6) . The deficiency in functional ADAMTS-13 seen in TTP patients can be caused by genetic mutation (7) or by inhibitory antibodies (4, 5, 8) .
TTP reportedly occurs as a complication of several physiological and pathological states, including pregnancy, liver disease (9) and autoimmune disorders, such as systemic lupus erythematosis (SLE) or systemic sclerosis (10) . Antiphospholipid syndrome (APS) is another autoimmune disorder, which is characterized with thrombosis, obstetric complications and the presence of antiphospholipid antibodies (aPL) (11) . Little is known about the association between TTP and APS, however. Herein, we report a case of TTP with ADAMTS-13 deficiency caused by an inhibitor in a patient with aPL and Charcot-Marie-Tooth disease (CMT). from the beginning (walked at 24 months; first words at 36 months). At age 3 years, she was referred to an institution for orthopedically impaired children because of a gait abnormality and delayed language milestones. Electrodiagnostic studies at that time revealed normal conduction velocity in the motor nerves in the upper extremities, but no compound action potentials were elicited in the lower extremities. Electromyography of the tibialis anterior muscle showed a neurogenic pattern. Her development was moderately delayed, and she had an IQ score of 54 points at 6 years of age. A neurological examination at age 10 years revealed distal muscle atrophy with absent tendon reflexes in the lower extremities. A presumptive diagnosis of CMT was made by the neurologist. At age 12 years, the patient presented with immune thrombocytopenic purpura (ITP), which was diagnosed through periodic inspection, and was treated with intravenous gamma globulin and prednisone for one month. The thrombocytopenia subsequently disappeared without specific treatment. By age 26 years she showed weakness in both lower extremities, which had progressed over time and was associated with significant distal muscle wasting in the lower extremities and hands. There were no other serious illnesses or injuries. On admission, the patient's body temperature was 37.5 , her pulse rate was 125 beats/min and her blood pressure was 128/60 mmHg. Physical examination revealed anemia in the conjunctivas, bleeding in the bulbar conjunctivas, petechiae over the entire body, permanent quadriplegia and amyotrophy associated with CMT, as well as mental retardation. There was no manifestation suggestive of SLE.
The results of routine laboratory tests done at the time of admission are shown in Table 1 . Complete blood counts re- vealed severe anemia with reticulocytosis, red cell fragmentation, and thrombocytopenia. Urinalysis and stool examination revealed the presence of occult blood. Blood chemistry showed elevated serum levels of indirect bilirubin and lactate dehydrogenase (LDH). Both direct and indirect Coombs tests were negative. Anti-nuclear antibodies were weakly positive (nucleolar + speckled pattern). Serum complement levels were reduced, but cryoglobulin levels were not evaluated. Coagulation tests showed a slightly elevated level of fibrinogen degradation products. A bone marrow aspirate showed the presence of hyperplastic megakaryocytes. Magnetic resonance imaging (MRI) of the brain revealed a fresh cerebral infarction in the left precentral gyrus, and multiple lacunar infarctions in the bilateral cerebral white matter (Fig. 1) . Figure 2 shows the clinical course. The patient was treated with high-dose gamma globulin, oral prednisolone, and platelet concentrate (PC) for a suspected recurrence of her ITP with severe bleeding tendency; however, the platelet count declined to 1,000/μL on day 4. Fresh frozen plasma (FFP) was then infused for suspected thrombotic microangiopathic hemolytic anemia (TMHA). The thrombocytopenia and elevated LDH values immediately improved after beginning the infusions of FFP, and the administration was continued for 16 days.
Serological parameters over the clinical course are shown in Table 2 . In the plasma sample collected on day 4, before the start of FFP infusion, ADAMTS-13 activity was markedly reduced, and an inhibitor of ADAMTS-13 was detected, as were anti-cardiolipin IgG and IgM antibodies (aCL). From these findings, the patient was diagnosed TTP with probable APS. By day 19, ADAMTS-13 activity and haptoglobin levels had normalized, and the ADAMTS-13 inhibitor had disappeared from the plasma. The titer of the aCL IgG had also declined to a level within the normal range during the course of treatment. Following her successful treatment with infusions of FFP, the patient was maintained on prednisolone and a low dose aspirin for 18 months without a relapse of TTP/APS.
Discussion
CMT represents a group of inherited peripheral neuropathies characterized by progressive weakness and atrophy of the distal limb muscles and sensory abnormalities. The classification of CMT is complex and undergoes constant revision as new genes and mutations are discovered. For example, mutations in the neurofilament light chain (NEFL) gene cause autosomal dominant neuropathies that are classified as either CMT2E or CMT1F (12, 13) , and some cases with associated mental retardation have been reported (13) . Recently, a mutation of dynamin 2 (DNM2) was identified in three unrelated families affected by CMT (14) . DNM2 belongs to a family of large GTPases and has been shown to regulate cell migration by modulating endocytosis of platelet-derived growth factor (PDGF) receptors (15) . Thus, one possible cause of the thrombocytopenia or thrombosis associated with CMT might be dysregulation of cell migration due to DNM2 abnormality. Interestingly, in some families, CMT with a DNM2 mutation is associated with hematological abnormalities such as neutropenia, anemia, and thrombocytopenia (16) . In the present patient, gene abnormalities associated with CMT could not be confirmed by Affymetrix DNA microchip array analysis (kindly performed by Dr. Hiroshi Takashima, Kagoshima University); nonetheless, a presumptive diagnosis of CMT was made by a neurologist based on neurologic findings typical of CMT and the family history. However, there have been no previous reports suggesting a relationship between CMT and APS, or between CMT and TTP. aPL are frequently found in patients initially diagnosed with ITP, and in patients with ITP, the persistent presence of aPL is an important risk factor for the development of APS (17) . The present patient was diagnosed with ITP at age 12 years. Although aPL were not detected during the first episode of thrombocytopenia, their appearance could have been the first symptom of APS. The old multiple lacunar infarctions observed in the bilateral cerebral white matter were also probably associated with APS. Serum complement levels were decreased in our patient at the time of admission, and hypocomplementemia is common among patients with primary APS (18) . Although it is possible for SLE or cryoglobulinemia to cause hypocomplementemia, we suggest it was more likely related to the primary APS.
The original classification criteria for APS formulated in Sapporo in 1998 were revised as an international consensus statement in 2006 (19, 20) . This was because the high frequencies of aPL in older populations and thromboembolic disease in hospitalized patients suggests that the Sapporo criteria would not be suitable for these populations. In the revised classification criteria, ischemic stroke is the only neurological manifestation accepted as a clinically diagnostic criterion for APS. The present patient met this clinical criterion for the association of aPL with stroke, but she did not meet the laboratory requirement of the revised criteria, as her plasma aCL IgG and/or IgM titers were not >40 IU or > the 99th percentile. Thus, her initial diagnosis of primary APS met the Sapporo criteria but did not meet the revised criteria for a definitive diagnosis of APS. Although TTP can be a complication of various autoimmune disorders, TTP associated with primary APS is uncommon in the literature. The first case was reported by Durand et al in 1991 (21) , and there have been several others since then (22) (23) (24) (25) . Among these cases, ADAMTS-13 activity and/or the presence of ADAMTS-13 inhibitors were assessed in only four, including the present case (Table 3) . This is because ADAMTS-13 activity generally could not be assayed before 1996. It was at that time that a method for measuring cleavage of VWF by ADAMTS-13 was developed by Furlan et al (26) and Tsai (27) . Moreover, in 2005 Kokame et al reported a fluorescence resonance energy transfer (FRET) assay for measuring ADAMTS-13 activity (FRETS-VWF73 assay) (28) . At present, the FRETS-VWF 73 assay is widely used and accepted for measuring ADAMTS-13 activity. For that reason, we used the FRETS-VWF73 assay to measure ADAMTS-13 activity in our patient.
We report the eighth case of TTP with primary APS and the fourth case of TTP with ADAMTS-13 deficiency caused by an inhibitor in a patient with primary APS. In all eight cases the bleeding tendency and neurologic disturbances associated with TTP were improved by plasma exchange and administration of FFP and steroid. Moreover, in the three cases, including the present case, in which plasma levels of ADAMTS-13 activity and inhibitors of ADAMTS-13 were analyzed, activity increased to the normal range and inhibitors disappeared after the therapy. According to the revised classification criteria of 2006, however, none of these cases could be diagnosed as primary APS because the definition of aPL-associated thrombocytopenia excludes patients with TTP. We suggest that TTP due to ADAMTS-13 deficiency should be considered independent of APS in these criteria.
A peculiar presentation of APS termed catastrophic APS (CAPS) features TMHA. Although CAPS is very rare, it is a potentially life-threatening condition with small vessel occlusions in multiple organs that clinicopathologically resemble TTP. A recent review of 280 patients with CAPS revealed that 46% suffered from primary APS and 44% died at the time of a CAPS event (29) . On the other hand, treatment with a combination of anticoagulation, steroid and plasma exchange enabled recovery from CAPS in some cases. Although this is the same strategy used to treat TTP, the authors did not refer to a relationship between CAPS and TTP in their review. If ADAMTS-13 activity is not assessed, TTP and APS (especially the CAPS variant) may be difficult to discriminate because widespread microvascular thrombosis is common to both. Austin et al (30) hypothesized that aberrations in ADAMTS-13 may occur in APS and tested that idea in a group of 68 patients with aPL. Among them, 33 (49%) tested positive for anti-ADAMTS-13 IgG, and 22 (33%) exhibited low ADAMTS-13 activity (median 34%). In addition, as shown in Table 3 , previously reported cases of TTP associated with primary APS exhibited severe ADAMTS-13 deficiency (0-10%) caused by the inhibitor. Why APS is sometimes complicated by TTP remains unknown, but the observations of Austin et al (30) suggest that ADAMTS-13 derangement may occur in APS and may perhaps contribute to the thrombogenesis seen in autoimmune conditions other than TTP. This connection puts CAPS outside the revised classification criteria for APS 2006.
Endothelial damage, regardless of its etiology, can result in widespread release of UL-VWFM and thus induction of thrombosis (31) . Diez-Ewald et al (32) found that vWF levels were significantly elevated in patients with lupus anticoagulant. Reduced ADAMTS-13 activity may be an additional risk factor for arterial thrombosis in patients with aPL. We suggest that it would be beneficial to systematically screen for ADAMTS-13 activity and inhibitors of ADAMTS-13 in all patients with clinical and laboratory features of TMHA in autoimmune disorders such as APS. In addition, if ADAMTS-13 deficiency or the presence of ADAMTS-13 inhibitors is detected, plasma exchange or FFP with steroids is the most important component of treat-ment and is indicated as the first-line treatment for the risk of thrombosis.
It seems clear that one-third to one-half of patients with TTP tend to relapse, and relapses are associated with persistent or recurrent severe ADAMTS-13 deficiency (33) . Regular laboratory monitoring for ADAMTS-13 activity and inhibitors after treatment with PE could be important for a prediction of relapse of TTP.
Conclusion
We report a case of TTP with severe ADAMTS-13 deficiency caused by an inhibitor in a patient with aPL and CMT. We successfully treated the patient with prednisolone and infusion of FFP. Although the accepted definitions make the relationship between TTP and APS, especially CAPS, complicated, it is clinically important to test for ADAMTS-13 activity and for the presence of ADAMTS-13 inhibitors in patients with TMHA in autoimmune disorders such as APS before making a decision about treatment, including plasma exchange or infusion of FFP.
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